Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease

被引：58

作者：

Dodge, James C. ^{[1
]}

Clarke, Jennifer ^{[1
]}

Treleaven, Christopher M. ^{[1
]}

Taksir, Tatyana V. ^{[1
]}

Griffiths, Denise A. ^{[1
]}

Yang, Wendy ^{[1
]}

Fidler, Jonathan A. ^{[1
]}

Passini, Marco A. ^{[1
]}

Karey, Kenneth P. ^{[1
]}

Schuchman, Edward H. ^{[2
]}

Cheng, Seng H. ^{[1
]}

Shihabuddin, Lamya S. ^{[1
]}

机构：

[1] Genzyme Corp, Framingham, MA 01701 USA

[2] Mt Sinai Sch Med, New York, NY 10029 USA

来源：

EXPERIMENTAL NEUROLOGY | 2009年 / 215卷 / 02期

关键词：

Intracerebioventricular delivery; Acid sphingomyelinase; Sphingomyelin; Lysosomal storage disease; Acid sphingomyelinase knockout mouse; ENZYME-REPLACEMENT THERAPY; AAV8-MEDIATED HEPATIC EXPRESSION; CONVECTION-ENHANCED DELIVERY; LYSOSOMAL STORAGE PATHOLOGY; INTRACEREBRAL TRANSPLANTATION; GAUCHERS-DISEASE; DEFICIENT MICE; GENE-THERAPY; AAV VECTOR; A-DISEASE;

D O I：

10.1016/j.expneurol.2008.10.021

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Niemann-Pick A (NPA) disease is a lysosomal storage disorder (LSD) caused by a deficiency in acid sphingomyelinase (ASM) activity. Previously, we showed that the storage pathology in the ASM knockout (ASMKO) mouse brain could be corrected by intracerebral injections of cell, gene and protein based therapies. However, except for instances where distal areas were targeted with viral vectors, correction of lysosomal storage pathology was typically limited to a region within a few millimeters from the injection site. As NPA is a global neurometabolic disease, the development of delivery strategies that maximize the distribution of the enzyme throughout the CNS is likely necessary to arrest or delay progression of the disease. To address this challenge, we evaluated the effectiveness of intracerebroventricular (ICV) delivery of recombinant human ASM into ASMKO mice. Our findings showed that ICV delivery of the enzyme led to widespread distribution of the hydrolase throughout the CNS. Moreover, a significant reduction in lysosomal accumulation of sphingomyelin was observed throughout the brain and also within the spinal cord and viscera. Importantly, we demonstrated that repeated ICV infusions of ASM were effective at improving the disease phenotype in the ASMKO mouse as indicated by a partial alleviation of the motor abnormalities. These findings support the continued exploration of ICV delivery of recombinant lysosomal enzymes as a therapeutic modality for LSDs such as NPA that manifests substrate accumulation within the CNS. (c) 2008 Elsevier Inc. All rights reserved.

引用

页码：349 / 357

页数：9

共 33 条

[1] Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II:: Results of a phase I/II clinical trial [J].